New shot aims to control prostate cancer by blocking testosterone
NCT ID NCT06395753
First seen Oct 31, 2025 · Last updated May 13, 2026 · Updated 23 times
Summary
This study tests a new long-acting injection called Debio 4228 for men with advanced prostate cancer. The drug blocks a hormone that tells the body to make testosterone, which can fuel cancer growth. The goal is to find the right dose that safely lowers testosterone levels to slow the disease. About 66 men with advanced prostate cancer that needs ongoing hormone therapy will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AP Medical Research
Miami, Florida, 33165, United States
-
AP-HP Hopital Pitie-Salpetriere
Paris, 75013, France
-
AZ Groeninge
Kortrijk, 8500, Belgium
-
Alarcon Urology Center
Montebello, California, 90640, United States
-
Bakersfield Institute of Advanced Urology
Bakersfield, California, 93301, United States
-
CHRU de Brest - Hopital Morvan
Brest, 29200, France
-
CHU Angers
Angers, 49933, France
-
CHU de Nantes - Hôtel Dieu
Nantes, 44093, France
-
Carolina Urologic Research Center
Myrtle Beach, South Carolina, 29572, United States
-
Centre Georges Francois Leclerc
Dijon, 21000, France
-
Centre Jean Perrin
Clermont-Ferrand, 63011, France
-
Corporacio Sanitaria Parc Tauli - Hospital de Sabadell
Sabadell, 08208, Spain
-
East Valley Urology Center of Arizona
Queen Creek, Arizona, 85140, United States
-
Grimaldi Urology
Chula Vista, California, 91910, United States
-
Hospital Clinic Barcelona
Barcelona, 8036, Spain
-
Hospital Clinico San Carlos
Madroñera, 28040, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Instituto Valenciano de Oncologia
Valencia, 46009, Spain
-
Oregon Urology Institut
Springfield, Oregon, 97477, United States
-
Summit Cancer Centers of North Spokane
Spokane, Washington, 99208, United States
-
Tower Urology,
Los Angeles, California, 90048, United States
-
Urologic Surgeons of Arizona
Mesa, Arizona, 85206, United States
-
Urology Center of Southern California
Murrieta, California, 92563, United States
-
Urology of Virginia
Virginia Beach, Virginia, 23462, United States
-
Valley Urology
Fresno, California, 93722, United States
Conditions
Explore the condition pages connected to this study.